( MENAFN - GlobeNewsWire - Nasdaq) VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the“ Company ”,“ Rakovina ”, or“ Rakovina Therapeutics ”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the closing of a $3.0 million private placement. The private placement consists of 50,000,000 units (the“ Units ”) at a price of $0.06 per Unit. Each Unit consists of one common share of the Company (each, a“ Common Share ”) and one Common Share purchase warrant (each, a“ Warrant ”). Each Warrant entitles the holder thereof to subscribe for and purchase one Common Share of the Company for a period of 24 months from the date of issue at a price of $0.10 per Common Share. Rakovina retains the right to accelerate the Warrant exercise period if, upon written notice to the holder, the 20-day volume-weighted average price of its Common Shares exceeds $0.30. In connection with the Private Placement, the Company paid cash finder's fees to Canaccord Genuity Corp., Ventum Financial Corp., Haywood Securities Inc., Research Capital Corporation, Hampton Securities Limited, Ewing Morris & Co. Investment Partners Ltd. and Leede Financial Inc. (each a“ Finder ”, and collectively, the“ Finders ”) in the aggregate amount of $180,841 and issued a total of 3,021,872 non-transferable finder's warrants (each, a“ Finder's Warrant ') to the Finders, in accordance with the policies of the TSX Venture Exchange (the“ TSXV ”). Each Finder's Warrant entitles the holder thereof to subscribe for and purchase one Common share of the Company for a period of 24 months from the date of issue at a price of $0.10 per Common Share, subject to acceleration on the same terms as the Warrants issued in connection with the private placement. The private placement is subject to the final acceptance of the TSXV and all securities issuable in connection with the private placement are subject to a hold period of four months plus one day from the date of issuance, in accordance with applicable securities laws. The proceeds of the private placement will be used to accelerate both discovery and development of the Company's proprietary drug candidates, shortlisted from the Deep Docking and Variational AI platforms. “This overwhelming response from our investors underscores the strength of our science, the extraordinary talent and dedication of our team and the transformative potential of our therapies,” said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics.“We are deeply grateful for the trust placed in us and remain resolute in our mission to utilize leading AI technologies to develop innovative solutions for cancer care.” The Company extends its heartfelt thanks to its investors, partners, and team for their unwavering support as Rakovina continues its work to bring new hope to patients and families affected by cancer. Rakovina is pleased to announce its engagement of Fairfax Partners Inc. as its Investor Relations (IR) partner. With extensive expertise in investor engagement strategies, Fairfax will implement a comprehensive six-month IR program designed to enhance Rakovina's market presence and expand its investor base. The program, which includes an option to renew for an additional six months, focuses on complementing traditional IR efforts with targeted online marketing campaigns, activation of a robust social media influencer network, and collaboration with external consultants and global wealth management channels. These initiatives will support Rakovina's strategic plan for 2025 by institutionalizing its investor base and strengthening its distribution capabilities. Under the agreement, Fairfax will receive a monthly fee of $5,000 plus GST, a one-time setup fee of $15,000 plus GST, and a marketing budget of $120,000 plus GST, disbursed as follows: $80,000 upon signing and $40,000 two months later. Services provided by Fairfax include inbound and outbound phone communications, website and social media management, marketing material preparation, news release support, and roadshow assistance, ensuring Rakovina's IR efforts align with market expectations. Fairfax Partners Inc., located at 306-1238 Seymour Street, Vancouver, BC, confirms that neither its directors nor officers hold any securities of Rakovina. For inquiries, please contact .... “We are thrilled to partner with the seasoned team at Fairfax Partners to expand our investor base and increase awareness of Rakovina Therapeutics' vision. Fairfax's creative and forward-thinking approach to investor relations will be a critical asset as we enter a pivotal year. By harnessing their extensive network and digital expertise, we aim to significantly enhance our market presence and deliver lasting value to our shareholders,” said Mr. Bacha. About Rakovina Therapeutics Inc. Rakovina Therapeutics Inc. is dedicated to developing innovative cancer therapies targeting the DNA-damage response. The company has established a development pipeline of novel DNA-damage response inhibitors by leveraging Artificial Intelligence (AI) to accelerate the identification and optimization of drug candidates. Rakovina Therapeutics aims to advance one or more of these candidates into human clinical trials in collaboration with pharmaceutical partners and secure marketing approvals from Health Canada, the U.S. Food and Drug Administration, and other international regulatory agencies. Further information may be found at . The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Notice Regarding Forward-Looking Statements: This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the terms of the private placement, the closing of the private placement, the receipt of final TSXV approval, the proposed business plan of the Company; the Company's commitment to advancing new cancer therapies; the ability of the Company to extract value from its AI collaborations; the Company's ability to execute on its business plans while maintaining high standards of research; the ability of Pharma Inventor Inc. to accurately provide medicinal chemistry support; the projected timeline and effectiveness of the Company's strategy to utilize the Deep Docking AI platform; and the Company's ability to generate shareholder value. Often, but not always, forward-looking statements can be identified by the use of words such as“plans”,“is expected”,“expects”,“scheduled”,“intends”,“contemplates”,“anticipates”,“believes”,“proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results“may”,“could”,“would”,“might” or“will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company's most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company's profile page at For Further Information Contact: David Hyman, Chief Financial Officer ... Invest Relations &Media Michelle Seltenrich ... 778-773-5432 MENAFN13122024004107003653ID1108991733 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
A cereal switch-up is stirring up sweet — well, mostly salty — discussion. Post Consumer Brands confirmed to TODAY.com that it’s discontinuing its beloved Oreo O’s cereal and replacing it with something new: Oreo Puffs. > 24/7 San Diego news stream: Watch NBC 7 free wherever you are It features chocolaty cereal puffs and mini marshmallows with the aim of creating a similar experience to dunking an Oreo cookie into a glass of milk. According to Post, Oreo Puffs are made with real Oreo cookie wafers — which are the cookies that sandwich the creme.. The new cereal will be available at retailers nationwide including Walmart and Target for an MSRP of $4.99. According to Post, Oreo Puffs are made with real Oreo cookie wafers — which are the cookies that sandwich the creme.. The new cereal will be available at retailers nationwide including Walmart and Target for an MSRP of $4.99. “With its introduction, OREO PUFFSTM cereal will replace OREO O’s® cereal on store shelves,” Post tells TODAY.com in an email. U.S. & World Bob Fernandez, 100-year-old Pearl Harbor survivor, dies peacefully at home 83 years after bombing Jay-Z rape accuser comes forward to NBC News, acknowledges inconsistencies in her allegations Oreo O’s was introduced to U.S. markets in 1997, stayed on shelves until 2007, and then was brought back in 2017 during a big wave of nostalgic marketing. And just like that ... it’s returned to the vault of cereals past. We’ll check back in about 10 years to see if it’s revived from its sugary slumber again. News of the swap has hit the crumb-filled corners of social media, with popular snack-spotting Instagram account Markie Devo posting about the new product and its predecessor. As usual, his comments section had thoughts. “They should’ve kept the rings but added marshmallows,” wrote one commenter. “Sooo coco puffs,” another said , referencing the General Mills-brand analog to the new cereal. “ya know some things just need to be left alone !!” wrote another, and one more added , “I’m tired of every cereal turning into puffs 😢.” Others were excited about the breakfast-basednews. “These sound amazing,” wrote one user, and another added , “Oh wow my kids would be all over this one!” “OREO Puffs Cereal is out now and will be REPLACING OREO O’s Cereal!” one more user wrote on a separate post about the cereal, adding they think the new cereal is an upgrade. “It’s disappointing whenever a beloved item becomes discontinued, but this is actually very exciting news for us because we believe marshmallows BELONG in OREO Cereal!” This story first appeared on TODAY.com . More from TODAY : Fortnite players will receive refunds for unwanted purchases. How to claim yours Savannah Guthrie reveals her family’s 2024 holiday card — with a surprise announcement Dad shares bittersweet video of when his 13-year-old confronted him about Santa: 'Oh my heart'SUNRISE, Fla. — Nikita Kucherov scored before he was ejected for kneeing Matthew Tkachuk, and the Tampa Bay Lightning beat the Florida Panthers 4-0 in a chippy game on Monday night. Jake Guentzel and Mitchell Chaffee also scored for Tampa Bay in its fifth win in six games. Brandon Hagel had an empty-netter, and Anthony Cirelli and Victor Hedman collected two assists apiece. Jonas Johansson made 36 saves in his first shutout of the season and No. 4 for his career. Florida had won four in a row, including a 4-2 victory at Tampa Bay on Sunday. Tkachuk had to be helped off the ice and to the dressing room after Kucherov crashed into his right leg late in the first period. Kucherov was given a five-minute major penalty and a game misconduct for the hit, and Tkahcuk returned a couple minutes into the second. Sergei Bobrovsky made 25 stops for the Panthers. Takeaways Lighting: Hagel scored a short-handed goal with 5:42 left. The Lighting allowed two short-handed goals in the opener of the home-and-home set. Tampa Bay Lightning right wing Mitchell Chaffee (41) scores against Florida Panthers goaltender Sergei Bobrovsky (72) during the first period of an NHL hockey game Monday, Dec. 23, 2024, in Sunrise, Fla. Credit: AP/Rhona Wise Panthers: Went 0 for 4 on the power play. They got off to a slow start and then played better in the second period, but couldn't finish their offensive chances. Key moment Chaffee made it 3-0 with his seventh goal of the season 16:24 into the first period. It was Tampa Bay's ninth power-play goal in December and No. 26 on the season. Key stat The Lightning were assessed nine penalties for a total of 37 minutes, and the Panthers were called for nine penalties for 26 minutes. Up next Both teams return to action on Saturday after the league's holiday break. The Panthers host Montreal, and the Lightning host the New York Rangers.
U.S. women’s national team goalkeeper Alyssa Naeher announced her retirement from international soccer Monday, ahead of the team’s two European friendlies against England and the Netherlands. She said the European matches will be her last. A 2019 World Cup winner and gold medalist at this summer’s Paris Olympics, she will continue playing for the Chicago Red Stars in the NWSL . She re-signed with Chicago in September to play through the 2025 season, which will be her 10th season with the club. Advertisement For the USWNT, however, it’s the end of a major goalkeeping era. Naeher’s career stands comfortably in the top three amongst other World Cup winners Briana Scurry and Hope Solo. “Every tear shed in the challenging times and disappointments made every smile and celebration in the moments of success that much more joyful,” Naeher wrote Monday in her announcement on social media. “This has been a special team to be a part of and I am beyond proud of what we have achieved both on and off the field.” View this post on Instagram A post shared by Alyssa Naeher (@alyssanaeher) Naeher made her debut a decade ago in December 2014, and after stints as the primary backup goalkeeper for the 2015 World Cup and 2016 Olympics, she took over the no. 1 spot following that quarterfinal exit. Ahead of what could be her two final games for the United States, she holds a record 88 wins, 14 draws and only six losses through 113 appearances. “Having the opportunity to be a part of the USWNT for the last 15 years has been the greatest honor,” she wrote. “When I began this journey, I never could have imagined where it would take me.” She earned her 100th cap earlier this year during the W Gold Cup and cemented her status not just as someone who could save penalty kicks, but convert them as well. In the W Gold Cup semifinal against Canada, she buried her attempt from the spot but also saved three of Canada’s attempts — marking her as the only USWNT goalkeeper to make three saves in a PK shootout. She’d repeat the same double later that spring, against Canada, during the SheBelieves Cup. At the Olympics this summer, she once again stepped up to help propel the USWNT to their gold medal victory, including a poster-worthy save against Brazil in the closing moments of the gold cup game at Parc des Princes. Off the field, she bonded with the forward line of Trinity Rodman , Sophia Smith and Mal Swanson (also known as “Triple Espresso”) who pulled her out of her shell . GO DEEPER USWNT on goalkeeper Alyssa Naeher: 'We’re making her a little more mushy gushy' “We’re making her a little more mushy gushy with us, which I think is nice,” Rodman said in France. “We’re opening up a side that I think has always been there, but it’s hidden a little bit.” (Top photo: Joe Robbins / Getty Images)
In a recent development, Apple criticized Meta Platforms, accusing the social media giant of requesting excessive access to its software tools. Apple claims this could jeopardize user privacy and security, further intensifying the competition between these tech behemoths. According to the European Union's Digital Markets Act, effective since last year, Apple is mandated to facilitate interoperability with competitors. Failure to comply could result in a hefty penalty of up to 10% of its global annual revenue. Thus far, Meta has filed 15 interoperability requests, seeking extensive access to Apple's technology. This exceeds the number submitted by any other company, raising concerns about potential privacy and security implications, as noted in Apple's report. (With inputs from agencies.)British Airways flight attendant 'suspended after callous post about Liam Payne'
As Nebraska's Democratic Party shrinks, some former party officials call for change
House Democrats who voted yes on NDAA lament transgender restrictions
AI Revolutionizes Data Governance: A New Era of Intelligent Management